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Objective: To investigate he effect of unopposed oestrogen on atheromatous carotid plaques. 
Subjects: Seventeen postmenopausaI women with known carotid isease. 
Methods: Carotid intimal thickness and plaque length and thickness were measured prior to and following 3 and 6 months 
of treatment, using Duplex ultrasound. A total of 22 plaques were followed up. 
Results: There was a reduction i plaque length after 3 (-8.14%, p = 0.001) and 6 months (-28%, p = 0.001) of treatment. 
The reduction i  plaque thickness (-18%, p = 0.004) was significant after 6 months of treatment. Reductions in intimaI 
thickness were not statistically significant. 
Conclusion: Our results uggest that oestrogen replacement is associated with significant plaque regression. 
Introduction 
Atherosclerosis related ischaemic vascular events kill 
more women than all forms of cancer together. 1 When 
compared to premenopausal women, the athero- 
sclerotic risk is 3.4 times higher in women after natural 
menopause, and up to 5.5 times greater in women 
after bilateral oophorectomy. 2 Animal models have 
provided suggestive vidence that atheroma forma- 
tion can be inhibited or even reversed by oestrogen 
treatment. The Clarkson group demonstrated a sig- 
nificant reduction in atherosclerosis in cynomolgus 
macaques fed a high fat diet and subsequently treated 
with oral contraceptives. They observed a deficit of 
50-75% from the expected plaque extent, rising to 
75-85% when considering the high risk group of 
animals onl~ i.e. animals with the most atherogenic 
lipid profile. 3 This finding is particularly interesting, 
as the atheroma of cynomolgus monkeys has been 
found resistant to regression with lipid lowering 
regimens. 4 Studies with angiographic end points have 
suggested that certain drug regimens may favour 
plaque regression in humans. 5 In this pilot study we 
set out to examine the effect of oestrogen replacement 
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on atheromatous plaques in carotid arteries of natu- 
rally or surgically menopausal women. 
The study was conducted in the Menopause 
Research Unit, Department of Obstetrics and Gynae- 
colog~ in collaboration with the Vascular Studies 
Unit, Department of Surgery, University of Leicester. 
Seventeen postmenopausal women with known 
carotid disease (mean age 66.7 years, range 55-75 
years), were treated with unopposed oestrogen for 6 
months. Their mean time since menopause was 13.6 
years (5-20 years). Two women were oophorecto- 
mised, the remaining 15 had undergone a natural 
menopause. Fourteen of the participating patients had 
an intact uterus. None of the participating women had 
a history of previous ex steroid exposure, i.e. contra- 
ceptive pill or HRT. Oestrogen replacement was given 
orally as Hormonin (600/~g micronised 17~-oestradiol, 
270/~g oestriol and 1.4 mg oestrone) one tablet daily. 
Two of the patients were taking concomitant Simvas- 
tatin, one a calcium antagonist and ten were taking 
Aspirin. 
The patients' carotid arteries were scanned using 
Diasonics VST Masters Duplex Ultrasound scanner 
(Diasonics Ultrasound Inc., Milpitas, CA, U.S.A.) with 
a 5 MHz linear array scan probe. Intimal thickness 
(IMT) as well as plaque length (PL) and plaque 
thickness (PT) were measured prior to treatment and 
subsequently, following 3 and 6 months of oestrogen 
replacement. A total of 22 atheromatous plaques were 
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found suitable for follow-up. All analysed scans were 
performed by one operator, who was blinded to 
previous measurements. 
Intra-observer variability was assessed in six serial 
measurements of IMT, PT and PL in six carotid 
arteries (4 patients), i.e. 108 serial measurements. The 
operator was blinded to all measurements during the 
validation session. Coefficient of Variation was 8% for 
IMT, 8% for PL and 10% for PT. 
Non-hysterectomised women underwent outpatient 
hysteroscopy under local anaesthetic following 6 
months of treatment, o exclude endometrial hyper- 
plasia. Standard panoramic CO2 hysteroscopy was 
performed as described previously. 6 Ten (67%) 
patients had maintained atrophic endometrium and in 
three (20%) patients it was found to be weakly 
proliferative. Two (13%) of the 15 patients with an 
intact uterus developed simple hyperplasia of the 
endometrium, which regressed to atrophic endomet- 
rium following a 6 week course of 10 mg Medrox- 
yprogesterone acetate daily. This was confirmed by a 
repeat hysteroscopy and endometrial biopsy. 
Obtained measurements of IMT, PT and PL were 
analysed using Analysis of Variance (ANOVA) for 
repeated measurements, All results are reported as 
percent reduction from baseline, with the 95% Con- 
fidence Interval (CI). 
A reduction in mean IMT was observed at 3 (-5%, 
95% C1-17 to 7) and at 6 months (-6%, 95% C1-26 to 
14). This was not statistically significant. Plaque length 
was significantly reduced at 3 (-8%, 95% C1-15 to -2, 
p = 0.001) and at 6 months (-28%, 95% CI -42 to -13, 
p = 0.001) of oestrogen replacement. Plaque thickness 
was also reduced at 3 (-1%, 95% C1-12 to 10, NS) and 
6 months (-18%, 95% CI -30 to -6, p=0.004) of 
treatment (Fig. 1). 
Although plaque recession has been observed with 
lipid lowering agents, ~the plaques of the two patients 
taking Simvastatin i this study in fact did not reduce 
in size. Calcium antagonists and Aspirin may act 
57 synergistically or inhibit atherogenesis, ' but there is 
no evidence that they contribute to plaques regression. 
Our data therefore suggest significant plaque regres- 
sion in association with oestrogen replacement. 
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Fig. 1. Reduction in plaque length and plaque thickness on 
oestrogen replacement (ERT) in % change from baseline with the 
95% Confidence Interval. (El) plaque length; ( , )  plaque thickness. 
*p < 0.004; **p < 0.001. 
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